> top > docs > PMC:7102591 > spans > 10152-17809 > annotations

PMC:7102591 / 10152-17809 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
308 27-45 Disease denotes rheumatic diseases MESH:D012216
309 49-65 Disease denotes viral infections MESH:D001102
333 918-920 Gene denotes CS Gene:1431
334 1293-1295 Gene denotes CS Gene:1431
335 1059-1061 Gene denotes CS Gene:1431
336 737-739 Gene denotes CS Gene:1431
337 408-410 Gene denotes CS Gene:1431
338 174-176 Gene denotes CS Gene:1431
339 782-790 Species denotes patients Tax:9606
340 896-904 Species denotes patients Tax:9606
341 1040-1048 Species denotes patients Tax:9606
342 1276-1283 Species denotes patient Tax:9606
343 194-196 Disease denotes RA MESH:D001172
344 377-379 Disease denotes RA MESH:D001172
345 443-455 Disease denotes inflammation MESH:D007249
346 463-465 Disease denotes RA MESH:D001172
347 589-599 Disease denotes infections MESH:D007239
348 677-686 Disease denotes infection MESH:D007239
349 765-775 Disease denotes infections MESH:D007239
350 779-781 Disease denotes RA MESH:D001172
351 879-889 Disease denotes infections MESH:D007239
352 893-895 Disease denotes RA MESH:D001172
353 1037-1039 Disease denotes RA MESH:D001172
354 1104-1120 Disease denotes viral infections MESH:D001102
355 1212-1229 Disease denotes Zoster infections MESH:D006562
371 1951-1953 Gene denotes CS Gene:1431
372 1327-1329 Gene denotes CS Gene:1431
373 1676-1678 Gene denotes CS Gene:1431
374 1735-1744 Species denotes MERS)-CoV Tax:1335626
375 1754-1762 Species denotes SARS-CoV Tax:694009
376 1530-1541 Species denotes respiratory Tax:12814
377 2102-2111 Species denotes influenza Tax:11309
378 1506-1522 Disease denotes viral infections MESH:D001102
379 1577-1588 Disease denotes lung damage MESH:D008171
380 1607-1611 Disease denotes ARDS MESH:D012128
381 1701-1733 Disease denotes Middle East respiratory syndrome MESH:D018352
382 1816-1833 Disease denotes lung inflammation MESH:D011014
383 1846-1861 Disease denotes alveolar damage MESH:D055370
384 1988-1997 Disease denotes infection MESH:D007239
385 2131-2140 Disease denotes mortality MESH:D003643
399 2683-2685 Gene denotes CS Gene:1431
400 2398-2400 Gene denotes CS Gene:1431
401 2869-2871 Gene denotes CS Gene:1431
402 2566-2568 Gene denotes CS Gene:1431
403 2379-2387 Species denotes patients Tax:9606
404 2499-2507 Species denotes patients Tax:9606
405 2632-2640 Species denotes patients Tax:9606
406 2220-2249 Disease denotes bacterial or fungal infection MESH:D001424
407 2451-2455 Disease denotes ARDS MESH:D012128
408 2646-2654 Disease denotes COVID-19 MESH:C000657245
409 2655-2664 Disease denotes infection MESH:D007239
410 2823-2831 Disease denotes COVID-19 MESH:C000657245
411 2832-2841 Disease denotes infection MESH:D007239
424 3054-3058 Gene denotes ACE2 Gene:302668
425 3081-3085 Species denotes rats Tax:10116
426 3219-3227 Species denotes patients Tax:9606
427 2991-3000 Chemical denotes Ibuprofen MESH:D007052
428 3274-3287 Chemical denotes acetaminophen MESH:D000082
429 2950-2966 Disease denotes viral infections MESH:D001102
430 3072-3080 Disease denotes diabetic MESH:D003920
431 3189-3197 Disease denotes COVID-19 MESH:C000657245
432 3198-3207 Disease denotes infection MESH:D007239
433 3330-3340 Disease denotes fever rise MESH:D005334
434 3348-3356 Disease denotes COVID-19 MESH:C000657245
435 3421-3430 Disease denotes infection MESH:D007239
449 4424-4427 Gene denotes MTX Gene:4580
450 3501-3509 Species denotes patients Tax:9606
451 4072-4080 Species denotes patients Tax:9606
452 4405-4413 Species denotes patients Tax:9606
453 4170-4182 Chemical denotes methotrexate MESH:D008727
454 4224-4242 Chemical denotes hydroxychloroquine MESH:D006886
455 3593-3595 Disease denotes RA MESH:D001172
456 3681-3683 Disease denotes RA MESH:D001172
457 3823-3832 Disease denotes infection MESH:D007239
458 3960-3969 Disease denotes infection MESH:D007239
459 4156-4165 Disease denotes infection MESH:D007239
460 4392-4401 Disease denotes infection MESH:D007239
461 4534-4543 Disease denotes infection MESH:D007239
463 4563-4570 Chemical denotes bDMARDs
469 4608-4616 Species denotes patients Tax:9606
470 4630-4637 Chemical denotes bDMARDs
471 4956-4963 Chemical denotes bDMARDs
472 4583-4592 Disease denotes infection MESH:D007239
473 4605-4607 Disease denotes RA MESH:D001172
483 5638-5641 Gene denotes TNF Gene:7124
484 5322-5330 Species denotes patients Tax:9606
485 5650-5658 Species denotes patients Tax:9606
486 5260-5269 Species denotes influenza Tax:11309
487 5363-5372 Species denotes influenza Tax:11309
488 5708-5717 Species denotes influenza Tax:11309
489 5179-5201 Disease denotes respiratory infections MESH:D012141
490 5275-5285 Disease denotes infections MESH:D007239
491 5762-5767 Disease denotes death MESH:D003643
493 5822-5830 Disease denotes tsDMARDs
512 7098-7103 Gene denotes JAK-1 Gene:3716
513 5938-5946 Species denotes patients Tax:9606
514 6243-6250 Species denotes patient Tax:9606
515 6352-6360 Species denotes patients Tax:9606
516 6519-6526 Species denotes patient Tax:9606
517 6643-6651 Species denotes patients Tax:9606
518 6021-6032 Chemical denotes tofacitinib MESH:C479163
519 6037-6048 Chemical denotes baricitinib MESH:C000596027
520 6152-6163 Chemical denotes tofacitinib MESH:C479163
521 6466-6477 Chemical denotes baricitinib MESH:C000596027
522 6662-6673 Chemical denotes tofacitinib MESH:C479163
523 6867-6877 Chemical denotes prednisone MESH:D011241
524 7125-7137 Chemical denotes upadacitinib MESH:C000613732
525 7142-7152 Chemical denotes filgotinib MESH:C584571
526 5863-5887 Disease denotes opportunistic infections MESH:D009894
527 5935-5937 Disease denotes RA MESH:D001172
528 6125-6135 Disease denotes infections MESH:D007239
529 6349-6351 Disease denotes RA MESH:D001172
531 7602-7630 Disease denotes respiratory virus infections

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T49 174-176 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T50 408-410 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T51 737-739 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T52 918-920 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T53 1059-1061 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T54 1293-1295 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T55 1327-1329 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T56 1341-1345 Body_part denotes hand http://purl.org/sig/ont/fma/fma9712
T57 1434-1438 Body_part denotes hand http://purl.org/sig/ont/fma/fma9712
T58 1530-1547 Body_part denotes respiratory tract http://purl.org/sig/ont/fma/fma265130
T59 1577-1581 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T60 1676-1678 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T61 1816-1820 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T62 1846-1854 Body_part denotes alveolar http://purl.org/sig/ont/fma/fma264783
T63 1951-1953 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T64 2398-2400 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T65 2566-2568 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T66 2683-2685 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T67 2869-2871 Body_part denotes CS http://purl.org/sig/ont/fma/fma284995
T68 7429-7433 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T16 1341-1345 Body_part denotes hand http://purl.obolibrary.org/obo/UBERON_0002398
T17 1434-1438 Body_part denotes hand http://purl.obolibrary.org/obo/UBERON_0002398
T18 1530-1547 Body_part denotes respiratory tract http://purl.obolibrary.org/obo/UBERON_0000065
T19 1577-1581 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T20 1816-1820 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

LitCovid_AGAC

Id Subject Object Predicate Lexical cue
p51590s23 3127-3135 PosReg denotes increase
p51595s16 4127-4134 NegReg denotes reduced

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T137 27-45 Disease denotes rheumatic diseases http://purl.obolibrary.org/obo/MONDO_0005554
T138 49-65 Disease denotes viral infections http://purl.obolibrary.org/obo/MONDO_0005108
T139 194-196 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T141 377-379 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T143 443-455 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T144 463-465 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T146 589-599 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T147 677-686 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T148 765-778 Disease denotes infections in http://purl.obolibrary.org/obo/MONDO_0005550
T149 779-781 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T151 879-892 Disease denotes infections in http://purl.obolibrary.org/obo/MONDO_0005550
T152 893-895 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T154 988-998 Disease denotes infectious http://purl.obolibrary.org/obo/MONDO_0005550
T155 1037-1039 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T157 1104-1120 Disease denotes viral infections http://purl.obolibrary.org/obo/MONDO_0005108
T158 1212-1218 Disease denotes Zoster http://purl.obolibrary.org/obo/MONDO_0005609
T159 1219-1229 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T160 1506-1522 Disease denotes viral infections http://purl.obolibrary.org/obo/MONDO_0005108
T161 1607-1611 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T162 1754-1762 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T163 1821-1833 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T164 1988-1997 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T165 2102-2111 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T166 2233-2249 Disease denotes fungal infection http://purl.obolibrary.org/obo/MONDO_0002041
T167 2240-2249 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T168 2451-2455 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T169 2646-2654 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T170 2655-2664 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T171 2823-2831 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T172 2832-2841 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T173 2950-2966 Disease denotes viral infections http://purl.obolibrary.org/obo/MONDO_0005108
T174 3189-3197 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T175 3198-3207 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T176 3348-3356 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T177 3421-3430 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T178 3482-3492 Disease denotes infectious http://purl.obolibrary.org/obo/MONDO_0005550
T179 3593-3595 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T181 3681-3683 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T183 3823-3832 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T184 3960-3969 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T185 4143-4165 Disease denotes hospitalized infection http://purl.obolibrary.org/obo/MONDO_0043544
T186 4156-4165 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T187 4392-4401 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T188 4534-4543 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T189 4583-4592 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T190 4605-4607 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T192 5132-5142 Disease denotes infectious http://purl.obolibrary.org/obo/MONDO_0005550
T193 5179-5201 Disease denotes respiratory infections http://purl.obolibrary.org/obo/MONDO_0024355
T194 5260-5269 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T195 5275-5285 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T196 5363-5372 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T197 5708-5717 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T198 5877-5887 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T199 5935-5937 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T201 6106-6112 Disease denotes Zoster http://purl.obolibrary.org/obo/MONDO_0005609
T202 6125-6135 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T203 6349-6351 Disease denotes RA http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383
T205 6792-6801 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T206 6897-6906 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T207 7230-7240 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T208 7614-7630 Disease denotes virus infections http://purl.obolibrary.org/obo/MONDO_0005108

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T81 120-123 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T82 301-304 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T83 391-393 http://purl.obolibrary.org/obo/CLO_0001313 denotes 36
T84 805-807 http://purl.obolibrary.org/obo/CLO_0053794 denotes 41
T85 935-936 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T86 1070-1071 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T87 1137-1138 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T88 1577-1581 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T89 1577-1581 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T90 1764-1766 http://purl.obolibrary.org/obo/CLO_0053799 denotes 45
T91 1816-1820 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T92 1816-1820 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T93 1916-1917 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T94 1999-2000 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T95 2052-2055 http://purl.obolibrary.org/obo/CLO_0050884 denotes ten
T96 2263-2267 http://purl.obolibrary.org/obo/CLO_0037048 denotes CI 1
T97 2417-2418 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T98 2484-2485 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T99 2580-2582 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T100 3001-3004 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T101 3313-3314 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T102 3371-3372 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T103 3535-3536 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T104 3574-3575 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T105 3646-3647 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T106 3798-3799 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T107 4086-4087 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T108 4116-4117 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T109 4281-4283 http://purl.obolibrary.org/obo/CLO_0001407 denotes 52
T110 4286-4287 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T111 4851-4852 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T112 5162-5169 http://purl.obolibrary.org/obo/CLO_0009985 denotes focused
T113 5298-5299 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T114 5428-5429 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T115 6113-6118 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T116 6387-6388 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T117 6405-6408 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T118 6855-6861 http://purl.obolibrary.org/obo/UBERON_0003100 denotes female
T119 7028-7029 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T120 7042-7044 http://purl.obolibrary.org/obo/CLO_0054055 denotes 71
T121 7262-7263 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T122 7429-7433 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T123 7473-7482 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T124 7491-7516 http://purl.obolibrary.org/obo/PR_000024990 denotes type I and II interferons
T125 7614-7619 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T68 17-22 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T69 110-116 Chemical denotes NSAIDs http://purl.obolibrary.org/obo/CHEBI_35475
T70 157-172 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T71 174-176 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T73 194-196 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T74 377-379 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T75 408-410 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T77 463-465 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T78 737-739 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T80 779-781 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T81 893-895 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T82 918-920 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T84 1037-1039 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T85 1059-1061 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T87 1293-1295 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T89 1327-1329 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T91 1676-1678 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T93 1951-1953 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T95 2154-2156 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T96 2251-2253 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T97 2398-2400 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T99 2566-2568 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T101 2683-2685 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T103 2869-2871 Chemical denotes CS http://purl.obolibrary.org/obo/CHEBI_73462|http://purl.obolibrary.org/obo/CHEBI_50858
T105 2926-2932 Chemical denotes NSAIDs http://purl.obolibrary.org/obo/CHEBI_35475
T106 2991-3000 Chemical denotes Ibuprofen http://purl.obolibrary.org/obo/CHEBI_5855
T107 3263-3269 Chemical denotes NSAIDs http://purl.obolibrary.org/obo/CHEBI_35475
T108 3593-3595 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T109 3681-3683 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T110 3762-3777 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T111 3860-3862 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T112 3985-3987 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T113 4170-4182 Chemical denotes methotrexate http://purl.obolibrary.org/obo/CHEBI_44185|http://purl.obolibrary.org/obo/CHEBI_50681
T115 4193-4195 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T116 4224-4242 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T117 4253-4255 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T118 4424-4427 Chemical denotes MTX http://purl.obolibrary.org/obo/CHEBI_44185
T119 4429-4431 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T120 4605-4607 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T121 5921-5931 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T122 5935-5937 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T123 6021-6032 Chemical denotes tofacitinib http://purl.obolibrary.org/obo/CHEBI_71200
T124 6152-6163 Chemical denotes tofacitinib http://purl.obolibrary.org/obo/CHEBI_71200
T125 6349-6351 Chemical denotes RA http://purl.obolibrary.org/obo/CHEBI_73810
T126 6662-6673 Chemical denotes tofacitinib http://purl.obolibrary.org/obo/CHEBI_71200
T127 6867-6877 Chemical denotes prednisone http://purl.obolibrary.org/obo/CHEBI_8382
T128 7114-7124 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T129 7463-7472 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T130 7502-7504 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T131 7646-7656 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T14 49-65 http://purl.obolibrary.org/obo/GO_0016032 denotes viral infections
T15 443-455 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T16 1104-1120 http://purl.obolibrary.org/obo/GO_0016032 denotes viral infections
T17 1346-1373 http://purl.obolibrary.org/obo/GO_0050777 denotes inhibit the immune response
T18 1358-1373 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T19 1462-1483 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammatory response
T20 1506-1522 http://purl.obolibrary.org/obo/GO_0016032 denotes viral infections
T21 1821-1833 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T22 2950-2966 http://purl.obolibrary.org/obo/GO_0016032 denotes viral infections
T23 7429-7451 http://purl.obolibrary.org/obo/GO_0002456 denotes cell-mediated immunity
T24 7429-7451 http://purl.obolibrary.org/obo/GO_0002449 denotes cell-mediated immunity
T25 7473-7482 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T53 0-83 Sentence denotes 4 The impact of drugs for rheumatic diseases on viral infections: what do we know?
T54 85-116 Sentence denotes 4.1 Corticosteroids and NSAIDs
T55 117-395 Sentence denotes It has now been more than 70 years that corticosteroids (CS) are pivotal for RA management and their role as remission inducer and bridging therapy for the management of disease flare has recently been renewed by the latest update of EULAR recommendations for RA treatment [36].
T56 396-695 Sentence denotes Even though CS efficacy in rapidly suppressing inflammation during RA initial course or flares is well recognized [37], their downside is the broad spectrum of adverse events, including severe infections and the high risk of developing comorbidities further increasing the risk of infection [27,38].
T57 696-965 Sentence denotes Although RCTs conducted in the past with CS showed no higher risk of infections in RA patients [[39], [40], [41]], cohort and case-control studies reported increased rates of overall infections in RA patients treated with CS, according to a dose-dependent fashion [42].
T58 966-1121 Sentence denotes The majority of these infectious events are of bacterial etiology, but RA patients receiving CS exhibit a greater risk of developing even viral infections.
T59 1122-1320 Sentence denotes As an example, a 2012 retrospective cohort-study demonstrated an increased risk of Herpes Zoster infections with an incidence rate of 8.54 cases per 1000 patient-years in CS treated population [29].
T60 1321-1617 Sentence denotes Thus, CS on the one hand inhibit the immune response and delay the clearance of the pathogen, while on the other hand they suppress the host inflammatory response, which in the case of viral infections of the respiratory tract is the major responsible for lung damage and occurrence of ARDS [43].
T61 1618-1867 Sentence denotes The latter represented the rational for the widely use of CS for the management of Middle East respiratory syndrome (MERS)-CoV [44] and SARS-CoV [45] outbreaks, both histologically characterized by lung inflammation and diffuse alveolar damage [46].
T62 1868-1998 Sentence denotes However, evidence from the literature points to a predominantly negative effect of CS in the management of this type of infection.
T63 1999-2191 Sentence denotes A 2019 systematic review and meta-analysis including ten observational studies (n = 6548) conducted in influenza reported increased mortality (risk ratio [RR] 1.75, 95% CI 1.3–2.4; p = .0002),
T64 2192-2406 Sentence denotes increased rate of secondary bacterial or fungal infection (RR 2·0, 95% CI 1·0–3·8; p = .04), and longer stay in an intensive care unit (mean difference 2.1, 95% CI 1.2–3.1; p < .0001) in patients receiving CS [47].
T65 2407-2584 Sentence denotes Moreover, a review exploring treatments for ARDS, including six studies with a total of 574 patients, concluded that insufficient evidence exists to recommend CS treatment [48].
T66 2585-2753 Sentence denotes Overall, no clear reason exists to expect that patients with COVID-19 infection will benefit from CS, and they might be more likely to be harmed with such therapy [49].
T67 2754-2913 Sentence denotes In fact, current interim guidance from WHO on clinical management of COVID-19 infection advises against the use of CS unless indicated for another reason [10].
T68 2914-2990 Sentence denotes The role of NSAIDs in the course of viral infections is still controversial.
T69 2991-3233 Sentence denotes Ibuprofen has been demonstrated to induce an overexpression of ACE2 when used in diabetic rats [50] and this effect might theoretically increase the susceptibility and worsen the clinical course of COVID-19 infection in treated patients [15].
T70 3234-3431 Sentence denotes In addition, the use of both NSAIDs and acetaminophen could be associated with a masking of the fever rise during COVID-19, resulting in a delay in diagnosis and proper management of the infection.
T71 3433-3446 Sentence denotes 4.2 csDMARDs
T72 3447-3737 Sentence denotes The most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51].
T73 3738-4011 Sentence denotes Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0).
T74 4012-4285 Sentence denotes Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52].
T75 4286-4432 Sentence denotes A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR:
T76 4433-4463 Sentence denotes 1.14; 95% CI, 0.98–1.34) [53].
T77 4464-4556 Sentence denotes However, all these reports provided no data on the risk of stratified infection by pathogen.
T78 4558-4570 Sentence denotes 4.3 bDMARDs
T79 4571-4734 Sentence denotes The risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54].
T80 4735-5004 Sentence denotes This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59].
T81 5005-5156 Sentence denotes Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61].
T82 5157-5242 Sentence denotes Data focused on viral respiratory infections in bDMARD cohort are still very limited.
T83 5243-5567 Sentence denotes The incidence of influenza-like infections observed in a cohort of 159 Italian patients treated with bDMARDs during the influenza season 2009–2010 was higher than the value reported in a wide sample of Italian population in the same period, even though no important complications or hospitalizations have been reported [62].
T84 5568-5815 Sentence denotes Overall, post-marketing experience is relatively reassuring that anti-TNF treated patients may not be at any specifically increased risk of influenza and that severe adverse outcomes, including death, do not appear to be exceedingly frequent [63].
T85 5817-5830 Sentence denotes 4.4 tsDMARDs
T86 5831-6141 Sentence denotes The overall risk of serious and opportunistic infections observed with Janus Kinase (JAK) inhibitors in RA patients is roughly comparable with bDMARDs [64,65], although these early years of tofacitinib and baricitinib use have raised the issue of an increased risk of Herpes Zoster virus (HZV) infections [66].
T87 6142-6386 Sentence denotes Data from tofacitinib pooled population enrolled in RCTs showed an HZV incidence rate of 4.0 per 100 patient-years (with greater incidence in geographic area with high HZV endemicity), doubling the rates of RA patients not receiving JAKis [67].
T88 6387-6538 Sentence denotes A similar picture has also been observed in the overall development program of baricitinib, with an incidence rate of 3.2 cases per patient-years [68].
T89 6539-6843 Sentence denotes The subsequent real-life experience from US claim databases revealed that the risk of HZV was higher in patients receiving tofacitinib compared to those treated with abatacept (aHR 2.01 (95% CI 1.40; 2.88) [69], and the risk of serious hospitalized HZV infection is 2-fold higher versus all bDMARDs [70].
T90 6844-7046 Sentence denotes Older age, female sex, prednisone >7.5 mg/day, prior infection, and greater number of hospitalizations were associated with increased HZV risk, whereas vaccination was associated with a lower risk [71].
T91 7047-7294 Sentence denotes More recent reports from RCTs conducted with novel JAK-1 selective inhibitors upadacitinib and filgotinib have basically confirmed the same trend, suggesting that the increase in HZV infections can be considered as a class effect of JAKis [72,73].
T92 7295-7553 Sentence denotes Although the exact mechanism by which HZV reactivation occurs in the context of JAK inhibition is unclear, the downregulation of both cell-mediated immunity and innate antiviral signaling through type I and II interferons (IFN) is likely to be involved [74].
T93 7554-7657 Sentence denotes Currently, no data are available on the risk of respiratory virus infections carried by JAK inhibitors.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T50 194-196 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T51 377-379 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T52 463-465 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T53 582-599 Phenotype denotes severe infections http://purl.obolibrary.org/obo/HP_0032169
T54 779-781 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T55 893-895 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T56 1037-1039 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T57 1838-1861 Phenotype denotes diffuse alveolar damage http://purl.obolibrary.org/obo/HP_0033006
T58 3330-3335 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T59 3593-3595 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T60 3681-3683 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T61 4605-4607 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T62 5179-5201 Phenotype denotes respiratory infections http://purl.obolibrary.org/obo/HP_0011947
T63 5863-5887 Phenotype denotes opportunistic infections http://purl.obolibrary.org/obo/HP_0031690
T64 5935-5937 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370
T65 6349-6351 Phenotype denotes RA http://purl.obolibrary.org/obo/HP_0001370

2_test

Id Subject Object Predicate Lexical cue
32205186-31396235-4826883 511-513 31396235 denotes 37
32205186-23192911-4826884 688-690 23192911 denotes 27
32205186-17870034-4826885 691-693 17870034 denotes 38
32205186-9251634-4826886 793-795 9251634 denotes 39
32205186-22393128-4826887 805-807 22393128 denotes 41
32205186-21884589-4826888 961-963 21884589 denotes 42
32205186-16195357-4826889 1613-1615 16195357 denotes 43
32205186-30917856-4826890 2402-2404 30917856 denotes 47
32205186-25896805-4826891 3087-3089 25896805 denotes 50
32205186-18668604-4826892 3733-3735 18668604 denotes 51
32205186-18260176-4826893 4281-4283 18260176 denotes 52
32205186-23192911-4826894 4727-4729 23192911 denotes 27
32205186-29180125-4826895 4730-4732 29180125 denotes 54
32205186-28298374-4826896 4772-4774 28298374 denotes 55
32205186-19022409-4826897 4813-4815 19022409 denotes 56
32205186-22796281-4826898 4819-4821 22796281 denotes 57
32205186-29592917-4826899 4825-4827 29592917 denotes 58
32205186-25975452-4826900 5000-5002 25975452 denotes 59
32205186-23800448-4826901 5152-5154 23800448 denotes 61
32205186-23256105-4826902 5563-5565 23256105 denotes 62
32205186-31733368-4826903 5986-5988 31733368 denotes 65
32205186-30219772-4826904 6534-6536 30219772 denotes 68
32205186-27113415-4826905 6746-6748 27113415 denotes 69
32205186-30183607-4826906 7042-7044 30183607 denotes 71
32205186-31692920-4826907 7287-7289 31692920 denotes 72
32205186-31520803-4826908 7290-7292 31520803 denotes 73
32205186-28250461-4826909 7549-7551 28250461 denotes 74